EUCTR2008-001352-51-AT进行中（未招募）不适用
A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12-Receptor Inhibitor, vs. Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) - INNOVATE - PCI
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.The patient is scheduled to undergo non-urgent PCI
- •2.The patient is between 18 and 75 years of age (inclusive) and willing to comply with the protocol
- •3.Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours of dosing. All patients must agree to use two forms of contraception during the study and for at least 4 weeks after their last dose. One of the methods must consist of oral or onjected contraceptives, transdermal hormone patch, subdermal implants, IUD with hormones or copper, or surgical sterilization.
- •4.The patient or legally acceptable representative is able to read and give written informed consent and has signed an informed consent form approved by the Investigator's IRB/IEC
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Estimated or measured weight < 55 kg
- •2.Acute non-ST-segment elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI) within 7 days prior to PCI
- •3.Chronic total occlusion or unprotected left main stenting
- •4.Cardiogenic shock (systolic blood pressure < 90 mm Hg requiring vasopressor or hemodynamic support)
- •5.Uncontrolled hypertension at the time of initial study drug administration defined as measured systolic blood pressure (SBP) > 190 mm Hg or diastolic blood pressure (DBP) > 108 mm Hg
- •6.Planned staged PCI
- •7.Planned surgery during the study period
- •8.Planned GP IIb/IIIa use
- •9.Patient has received a clopidogrel loading dose (=300 mg) within 7 days prior to randomization; patients on maintenance clopidogrel may be enrolled
- •10.The planned administration of the study-specified clopidogrel loading dose is >12 hours prior to PCI
- •11.Administration of thrombolytic agents, fondaparinux, or oral anticoagulants (e.g., warfarin) within the 7 days prior to PCI or requirement for chronic oral antocoagulation
- •12.Estimated creatinine clearance (e.g., Cockcroft-Gault) < 45 mL/min
- •13.Anemia with hemoglobin level < 10 g/dL
- •14.Thrombocytopenia (platelet count < 100,000/mm3)
- •15.Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 2.5 x the upper limit of normal (ULN) or other indication of clinically significant hepatic dysfunction
- •16.Facial or head trauma within the last 30 days
- •17.Intraocular hemorrhage within the last 30 days
- •18.Gastrointestinal bleeding within the last 30 days.
- •19.Active bleeding, or history of a bleeding disorder or known intracranial vascular malformation
- •20.History of any prior ischemic stroke or TIA within the last 5 years or intracranial hemorrhage, neoplasm, or arteriovenous malformation
- •21.Known allergy or contraindication to the components of PRT060128, aspirin, heparin, clopidogrel, glycoprotein IIb/IIIa inhibitors, or to any contrast media
- •22.Participation in any investigational drug study within 30 days prior to enrollment. Participation in a device trial prior to enrollment is acceptable
- •23.Prior participation in any study involving PRT060128
- •24.Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the patient’s risk by participating in the study. This would include, but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy or any unexplained blackouts
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12-Receptor Inhibitor, vs. Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Interventions (INNOVATE-PCI) - INNOVATE - PCIAdjunctive antiplatelet prior, during and after non-urgent percutaneous coronary intervention (PCI) in patients with coronary artery diseaseMedDRA version: 9.1Level: LLTClassification code 10065608Term: Percutaneous coronary interventionMedDRA version: 9.1Level: LLTClassification code 10011078Term: Coronary artery diseaseEUCTR2008-001352-51-DEPortola Pharmaceuticals Inc.800
进行中（未招募）
不适用
Randomized, Double-Blind, Active-Controlled Trial to Assess the Safety and Immunogenicity of Solvay's Cell-Derived Influenza Vaccine, Including Revaccination, in Elderly subjects.Prophylaxsis of seasonal influenzaMedDRA version: 12.0Level: HLTClassification code 10022005Term: Influenza viral infectionsEUCTR2009-014767-40-EEAbbott Biologicals B.V.600
进行中（未招募）
不适用
Randomized, Double-Blind, Active-Controlled Trial to Assess the Safety and Immunogenicity of Solvay's Cell-Derived Influenza Vaccine, Including Revaccination, in Elderly subjects.MedDRA version: 12.0Level: HLTClassification code 10022005Term: Influenza viral infectionsProphylaxsis of seasonal influenzaEUCTR2009-014767-40-LTAbbott Biologicals B.V.600
进行中（未招募）
不适用
Randomized, Double-Blind, Active-Controlled Trial to Assess the Safety and Immunogenicity of Solvay's Cell-Derived Influenza Vaccine, Including Revaccination, in Elderly subjects.Prophylaxsis of seasonal influenzaMedDRA version: 12.0Level: HLTClassification code 10022005Term: Influenza viral infectionsEUCTR2009-014767-40-CZAbbott Biologicals B.V.600
招募中
1 期
A randomized, double blind, controlled trial of efficacy of high intensity laser therapy (HILT) in neurophysiological results of carpal tunnel syndromecarpal tunnel syndromemild degreemoderate degreeHigh intensity laser therapyHILTcarpal tunnel syndromeCTSTCTR20170227003Faculty of Medicine Siriraj hospital, Mahidol university60